olanzapine + sugar pill
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pathological Gambling
Conditions
Pathological Gambling
Trial Timeline
Feb 1, 2007 → Mar 1, 2009
NCT ID
NCT00438776About olanzapine + sugar pill
olanzapine + sugar pill is a phase 3 stage product being developed by Eli Lilly for Pathological Gambling. The current trial status is completed. This product is registered under clinical trial identifier NCT00438776. Target conditions include Pathological Gambling.
What happened to similar drugs?
1 of 3 similar drugs in Pathological Gambling were approved
Approved (1) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00438776 | Phase 3 | Completed |
Competing Products
4 competing products in Pathological Gambling
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 40 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 40 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 32 |
| Gadoversetamide | Guerbet | Approved | 33 |